Aytu BioScience

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Aytu BioScience reports robust Q3 performance, eyes growth through innovation

Aytu BioScience delivered strong financial results in Q3 2024, with notable revenue and margin improvements. The company's strategic focus on specialty pharmaceuticals and operational efficiency bodes well for future growth. While challenges like supply chain disruptions exist, Aytu is poised for continued success through innovation and market opportunities.

Aytu BioScience reports robust earnings, focuses on growth strategies

Aytu BioScience demonstrated strong financial performance with improved EBITDA and strategic repositioning
While facing challenges in certain portfolio revenues, the company is focused on growth opportunities
Strategic initiatives like the RxConnect program and product expansion are key strengths
Addressing market challenges and seizing growth opportunities will be crucial for future success

Aytu BioPharma reports first-ever positive net income in Q1 2025

Aytu BioPharma delivered a strong performance in Q1 2025, achieving positive net income, sustained profitability, and operational efficiency amidst market challenges.
The company's focus on optimizing operations, reducing expenses, and pursuing growth opportunities positions it well for future revenue expansion and market competitiveness.
While facing challenges in a dynamic market environment, Aytu BioPharma has opportunities to leverage its strengths in key portfolios and strategic initiatives for sustained growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

On March 10, specialty pharmaceutical maker Aytu Bioscience Inc. (NASDAQ: AYTU) announced that it had licensed North American rights to distribute a coronavirus test kit div.connatix{margin: 1.5em 0;} div.connatix img {margin: unset;}   manufactured by China’s Zhejiang Orient Gene Biotech.

Why Coronavirus Test Competition Shocked Aytu Bioscience Stock

Altimmune

Clorox

Co-Diagnostics

Quest Diagnostics

Gilead Sciences

Inovio Pharmaceuticals

Lakeland Industries

NanoViricides

Novavax

Zoom Video

Markets looked like they would be crushed yet again on Monday despite the emergency Federal Reserve rate cut announced on Sunday.

How Coronavirus Stocks Were Holding Up in Monday’s Sell-Off

Can-Fite BioPharma Ltd.

Enanta Pharmaceuticals

La Jolla Pharmaceutical

Eli Lilly

OPKO Health

Roche Holding AG

The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus.

The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals

Markets were crushed again on Thursday after President Trump announced a travel ban to Europe on Wednesday night.

How Coronavirus Stocks Responded to Thursday’s Sell-Off

As of late, it has definitely been a great time to be an investor in Aytu BioScience, Inc. (AYTU).

Aytu BioScience, Inc. (AYTU) Shares March Higher, Can It Continue?

It is not a new scenario where an illness or problem starts to become a big deal in the public and there is a small-cap company that “has a solution for that” which happen to be known by very few investors and even fewer members of the public.

The Coronavirus Diagnostics Trade Gets a New Stock Favorite

Aytu Bioscience, Inc. (AYTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

All You Need to Know About Aytu Bioscience, Inc. (AYTU) Rating Upgrade to Buy

Aytu BioScience's (AYTU) CEO Josh Disbrow on Q2 2020 Results - Earnings Call Transcript

Aytu Bioscience, Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Aytu Bioscience, Inc. (AYTU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Aytu BioScience, Inc. (AYTU) CEO Joshua Disbrow on Q1 2020 Results - Earnings Call Transcript

Aytu Bioscience, Inc. (AYTU) delivered earnings and revenue surprises of -6.67% and -0.69%, respectively, for the quarter ended September 2019.

Aytu Bioscience, Inc. (AYTU) Reports Q1 Loss, Lags Revenue Estimates

Aytu BioScience, Inc. (AYTU) CEO Josh Disbrow on Q4 2019 Results - Earnings Call Transcript

Aytu BioScience (NASDAQ: AYTU) announced the publication of clinical study results demonstrating the effectiveness of Natesto regardless of patients' baseline Hypogonadism severity.

Aytu BioScience Shares Clinical Results For Natesto Testosterone Medication

Aytu BioScience, Inc. (AYTU) CEO Josh Disbrow on Q3 2019 Results - Earnings Call Transcript

Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aytu Bioscience, Inc. (AYTU) Moves to Buy: Rationale Behind the Upgrade

Aytu Bioscience, Inc. (AYTU) Upgraded to Buy: What Does It Mean for the Stock?

News for Aytu BioScience Stock (AYTU)